Your browser is no longer supported. Please, upgrade your browser.
Settings
BMY Bristol-Myers Squibb Company daily Stock Chart
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E60.43 EPS (ttm)1.07 Insider Own0.10% Shs Outstand1.67B Perf Week-6.11%
Market Cap107.82B Forward P/E28.06 EPS next Y2.30 Insider Trans-17.35% Shs Float1.67B Perf Month-3.73%
Income1.79B PEG3.30 EPS next Q0.36 Inst Own72.90% Short Float1.35% Perf Quarter0.75%
Sales16.38B P/S6.58 EPS this Y-22.10% Inst Trans0.03% Short Ratio3.39 Perf Half Y5.50%
Book/sh9.07 P/B7.13 EPS next Y30.39% ROA5.40% Target Price70.72 Perf Year33.07%
Cash/sh3.28 P/C19.69 EPS next 5Y18.32% ROE11.80% 52W Range46.72 - 70.54 Perf YTD10.79%
Dividend1.48 P/FCF- EPS past 5Y-5.90% ROI6.40% 52W High-8.47% Beta0.24
Dividend %2.29% Quick Ratio1.60 Sales past 5Y-3.30% Gross Margin77.40% 52W Low38.19% ATR1.16
Employees25000 Current Ratio1.80 Sales Q/Q7.00% Oper. Margin24.00% RSI (14)34.95 Volatility2.14% 1.60%
OptionableYes Debt/Eq0.49 EPS Q/Q-140.00% Profit Margin10.90% Rel Volume0.60 Prev Close64.66
ShortableYes LT Debt/Eq0.44 EarningsJul 23 BMO Payout149.50% Avg Volume6.67M Price64.57
Recom2.30 SMA20-5.12% SMA50-3.68% SMA2004.13% Volume2,532,344 Change-0.15%
Jun-17-15Initiated Piper Jaffray Underweight $60
May-14-15Initiated Berenberg Hold $70
Apr-21-15Upgrade Morgan Stanley Equal-Weight → Overweight $60 → $80
Feb-27-15Reiterated Argus Buy $70 → $78
Jan-12-15Reiterated Argus Buy $62 → $70
Oct-27-14Reiterated MKM Partners Sell $34 → $36
Jul-25-14Reiterated MKM Partners Sell $29 → $34
Jan-15-14Reiterated Argus Buy $58 → $62
Jan-10-14Upgrade Barclays Equal Weight → Overweight $52 → $65
Dec-20-13Reiterated UBS Neutral $48 → $54
Jul-29-13Reiterated Argus Buy $54
Jul-17-13Reiterated Barclays Equal Weight $42 → $45
Jun-04-13Reiterated Argus Buy $46 → $54
Apr-26-13Reiterated MKM Partners Sell $26 → $29
Apr-15-13Reiterated Barclays Equal Weight $33 → $42
Jan-25-13Reiterated UBS Neutral $34 → $36
Jan-09-12Reiterated Barclays Capital Overweight $34 → $36
Oct-19-11Initiated MKM Partners Sell $26
Jun-27-11Reiterated UBS Neutral $28 → $30
Mar-31-11Downgrade Jefferies Buy → Hold $28.50
Jul-29-15 01:04PM  BRISTOL MYERS SQUIBB CO Financials
09:03AM  Bristol-Myers Squibb Co. Earnings Analysis: By the Numbers
09:01AM  Abbott Laboratories Earnings Analysis: By the Numbers
Jul-28-15 06:52PM  Google, Amazon And Microsoft Curb Spending To Boost Profits
06:47PM  Gilead beats Street 2Q forecasts on surge in sales, profit
05:55PM  Procter & Gambles New CEO Will Face No Shortage of Challenges at TheStreet
04:34PM  Gilead Lifts Sales View As Hep C Drugs Top
01:35PM  Drugmaker Pfizer tops Street 2Q forecasts, raises forecast
01:03PM  Pfizer, Merck Beat Q2 Views; Sanofi Makes PD-1 Deal at Investor's Business Daily
Jul-27-15 08:21AM  Short Sellers Run For Cover From Major Pharma at 24/7 Wall St.
07:00AM  European Medicines Agency Validates and Grants Accelerated Assessment of Marketing Authorization Application for Empliciti (elotuzumab) For the Treatment of Multiple Myeloma in Patients Who Have Received One or More Prior Therapies Business Wire
Jul-25-15 08:09PM  10-Q for Bristol-Myers Squibb Co. at Company Spotlight
10:03AM  Is Bristol-Myers Squibb Outpacing Johnson & Johnson? at Motley Fool
Jul-24-15 05:57PM  Bristol-Myers wins approval for 1st hepatitis C type 3 drug
05:42PM  UPDATE 2-AbbVie, Bristol-Myers get FDA nod for hep C treatments Reuters
02:06PM  FDA Approves Daklinza (daclatasvir) for the Treatment of Patients with Chronic Hepatitis C Genotype 3 Business Wire
01:20PM  Biogen's Big-Volume Plunge Marks End Of 5-Year Run
11:12AM  AbbVie: Beware the Biosimilars? at Barrons.com
09:04AM  Bristol-Myers Squibb (BMY) Earnings Report: Q2 2015 Conference Call Transcript at TheStreet
01:40AM  Bristol-Myers Pricey Pipeline at The Wall Street Journal
Jul-23-15 11:29PM  Edited Transcript of BMY earnings conference call or presentation 23-Jul-15 2:30pm GMT
05:50PM  3 Big-Cap Drugmakers Who Beat Q2 Earnings Estimates at Investor's Business Daily
05:45PM  Bristol-Myers Squibb Gets a Mixed Message From Investors at Motley Fool
04:01PM  Analyst's Key Takeaways From Eli Lilly, Bristol-Myer Squibb's Latest Conference Calls
01:48PM  Bristol-Myers' Pricey Pipeline at The Wall Street Journal
01:32PM  Bristol-Myers Beats on Q2 Earnings, Raises 2015 Guidance - Analyst Blog
01:04PM  Bristol-Myers Gets a Revenue Boost from Opdivo at The Wall Street Journal
12:59PM  Halftime's hottest trades today: Earnings season
12:47PM  Bristol's Earnings Beat Fails to Impress; Shares Fall 1.9% at Barrons.com
12:17PM  Health care on a hot streak
12:15PM  Cancer Drugs Lift Lilly's Outlook at Barrons.com
10:58AM  Lilly, Bristol-Myers Beat Q2 Views, Lift Guidance at Investor's Business Daily
10:55AM  Why Bristol-Myers Squibb Solid Earnings Beat Failed to Impress
09:40AM  Surging new drug sales highlight strong Bristol-Myers Q2
09:37AM  Valeant Earnings Soar On M&A, Organic Sales Growth at Investor's Business Daily
08:48AM  Bristol-Myers (BMY) Beats on Q2 Earnings, Updates View - Tale of the Tape
08:46AM  BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
08:21AM  Bristol beats forecasts, raises profit view, shares jump
07:47AM  Bristol-Myers reports 2Q loss
07:38AM  Bristol-Myers beats forecasts, raises full-year profit view
07:30AM  Bristol-Myers Squibb Reports Second Quarter Financial Results Business Wire
07:30AM  Bristol-Myers Raises Forecast as Sales and Profit Top Estimates at Bloomberg
07:07AM  Q2 2015 Bristol-Myers Squibb Co Earnings Release - Before Market Open
06:30AM  European Medicines Agency Validates Two Parallel Type II Variation Applications to Extend the Opdivo (nivolumab) Indication in Europe Business Wire
Jul-22-15 07:00PM  Investors join push for more transparency on drug trials at Financial Times
06:35PM  Brace yourself! Thursday is earnings palooza at CNBC
04:13PM  What's Coming For Large-Cap Pharma Stocks This Earnings Season?
03:30PM  Bristol-Myers' HIV-1 Inhibitor Gets Breakthrough Designation - Analyst Blog
06:15AM  Bristol-Myers Shares Come With an Unhealthy Dose of Optimism at TheStreet
Jul-21-15 05:00PM  Bristol-Myers' Opdivo Study Stopped Early, Meets Endpoint - Analyst Blog
04:20PM  Can Bristol-Myers (BMY) Keep its Earnings Streak Alive? - Analyst Blog
02:00PM  Second-Generation Investigational HIV-1 Maturation Inhibitor Demonstrates Positive New Phase IIa Results, Supporting Continued Development Business Wire
01:15PM  Bristol-Myers says HIV drug gets FDA incentives
09:40AM  Bristol-Myers Squibb Receives Breakthrough Designation for HIV Treatment at The Wall Street Journal
09:00AM  Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for Investigational HIV-1 Attachment Inhibitor for Heavily Treatment-Experienced Patients Business Wire
08:05AM  Potential Kidney Cancer Drugs Could Revolutionize Treatment at Motley Fool
04:51AM  Novartis bullish on Afinitor cancer drug despite new competition
Jul-20-15 06:50PM  Ethical-Drug Firms Horizon Pharma, Bristol-Myers Rally at Investor's Business Daily
02:33PM  Exelixis' Meteroric Rise From the Ashes at Motley Fool
01:44PM  Bristol-Myers cancer immunotherapy advances on two fronts
12:58PM  Top trades for the 2nd half
12:07PM  European Commission Approves Nivolumab BMS, the First PD-1 Immune Checkpoint Inhibitor in Europe Proven to Extend Survival for Patients with Previously-Treated Advanced Squamous Non-Small Cell Lung Cancer Business Wire
10:50AM  Bristol-Myers, Exelixis Drugs Score Vs. Kidney Cancer at Investor's Business Daily
09:57AM  Bristol-Myers Halts Trial Early After Success in Kidney Cancer at Bloomberg
08:01AM  CheckMate -025, a Pivotal Phase III Opdivo Renal Cell Cancer Trial, Stopped Early
08:00AM  CheckMate -025, a Pivotal Phase III Opdivo (nivolumab) Renal Cell Cancer Trial, Stopped Early Business Wire
Jul-18-15 08:02AM  6 Big-Cap Drugmakers Reporting Earnings Next Week at Investor's Business Daily
Jul-17-15 04:30PM  Bristol-Myers' HIV-1 Drug Evotaz Gets European Approval - Analyst Blog
Jul-16-15 04:50PM  Bristol-Myers Inks Another Fibrotic Disease Agreement - Analyst Blog
12:07PM  Bristol-Myers' HIV-1 Drug Approved In Europe
09:21AM  European Commission Approves Bristol-Myers Squibbs Evotaz (atazanavir and cobicistat fixed-dose combination) for the Treatment of HIV-1 Infection in Adults Business Wire
Jul-15-15 04:44PM  What Will Gilead Buy Next? 4 Possible Targets at Investor's Business Daily
08:30AM  MUSC and Bristol-Myers Squibb Announce Translational Research Collaboration Focused on Fibrotic Diseases Business Wire
Jul-13-15 12:36PM  Buy These 5 Rocket Stocks to Escape the Summer Doldrums -- Including One Jim Cramer Likes at TheStreet
12:15PM  Bristol-Myers Squibb (BMY) Stock Up As Jefferies Increases Price Target at TheStreet
Jul-09-15 05:26PM  Gilead's next target?
02:22PM  What Is the Potential Impact of Gilead's Harvoni Launching in Japan? at Motley Fool
01:20PM  Google locks up more space in 'essentially 100% leased' Kendall Center at bizjournals.com
11:51AM  5 Big Stocks to Trade for Gains as China Tumbles at TheStreet
Jul-08-15 01:42PM  Avoiding the noise with drugs thanks to Bristol Myers Squibb
Jul-07-15 05:00PM  ArQule Reports Interim Data from Colorectal Cancer Study - Analyst Blog
Jul-06-15 06:13PM  Your first trade for Tuesday at CNBC
05:59PM  Fast Money Final Trade: LLY, TLT, WTW & BMY
Jul-02-15 11:28AM  Biogen, AGTC Link Up To Develop Gene Therapy at Investor's Business Daily
Jun-30-15 04:02PM  Celgene bet $1 billion that this biotechs science can cure deadly cancers at Fortune
02:43PM  Why is Celgene So Darn Expensive? at Barrons.com
Jun-29-15 06:19PM  Your first trade for Tuesday, June 30 at CNBC
03:10PM  Alexandria Reveals 15-Year Anchor Lease with Bristol-Myers - Analyst Blog
10:24AM  Buy Sysco Foods, Bristol-Myers Now Before Their Dividend Payouts at TheStreet
Jun-26-15 05:05PM  Bristol-Myers Announces Job Cuts, Changes in R&D Sites - Analyst Blog
11:35AM  Is Big Pharma Advertising Getting Out of Control? at 24/7 Wall St.
11:20AM  Bristol-Myers Squibb's new R&D site will be about as big as Baxter's at bizjournals.com
08:30AM  Alexandria Real Estate Equities, Inc. Announces 15-Year Anchor Lease of 208,000 RSF with Bristol-Myers Squibb at 100 Binney Street at the Alexandria CenterĀ® at Kendall Square in Cambridge, MA PR Newswire
Jun-25-15 02:34PM  Bristol-Myers Squibb to open Cambridge R&D center at bizjournals.com
12:28PM  Bristol-Myers Squibb to shift research jobs
12:14PM  5 Huge Stocks to Trade for Huge Gains -- Must-See Charts at TheStreet
11:59AM  Bristol-Myers to Close Sites, Cut 100 Jobs at The Wall Street Journal
11:22AM  Bristol-Myers to close sites, cut 100 jobs at MarketWatch
11:08AM  Bristol-Myers to stop new antiviral drug research
11:06AM  Bristol-Myers Halts Virus-Drug Research, Cuts 100 Employees at Bloomberg
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular. The company's products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; and Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia. Its products also comprise Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia for use in treating patients with moderately to severely active rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders. In addition, it is developing Opdivo, a human monoclonal antibody, which is in Phase III trials for non-small cell lung cancer, renal cell cancer, and melanoma; Beclabuvir, a non-nucleoside NS5B inhibitor that is in Phase III development for the treatment of HCV; Elotuzumab, a humanized monoclonal antibody, which is in Phase III trials for the treatment of multiple myeloma; and BMS-663068, an investigational compound that is being studied in HIV-1. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Blin EmmanuelSVP, Head of CommercializationJul 02Option Exercise0.009510953Jul 07 05:13 PM
Gordon MurdoSVP, Head of Worldwide MarketsJul 01Option Exercise0.002,33502,540Jul 06 07:17 PM
Caldarella Joseph CSVP & ControllerJun 04Sale65.7116,9721,115,22959,284Jun 08 04:17 PM
JUDGE ANN POWELLSVP, Global Human ResourcesApr 01Option Exercise0.001,55409,047Apr 03 03:39 PM
Cuss Francis MEVP & CSOMar 16Option Exercise25.52114,0102,909,160380,699Mar 17 05:54 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 16Sale67.087,000469,56022,218Mar 16 07:02 PM
Cuss Francis MEVP & CSOMar 16Sale67.81114,6667,775,501266,033Mar 17 05:54 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 13Sale66.6759139,40231,015Mar 16 07:01 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 13Sale66.795,000333,97229,218Mar 16 07:02 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 10Option Exercise0.002,068042,368Mar 12 06:53 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.005,287035,218Mar 12 06:54 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 10Option Exercise0.003,271052,348Mar 12 06:54 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.008,0190269,160Mar 12 06:54 PM
Caforio GiovanniChief Operating OfficerMar 10Option Exercise0.0010,579071,322Mar 12 06:54 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.001,788050,485Mar 12 06:55 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.005,212058,799Mar 12 06:55 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.002,977076,835Mar 12 06:55 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0013,2390184,290Mar 12 06:55 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 10Option Exercise0.0048,8500411,731Mar 12 06:56 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 10Option Exercise0.009,9970307,535Mar 12 06:53 PM
JUDGE ANN POWELLSVP, Human ResourcesMar 10Option Exercise0.004,54608,057Mar 12 06:53 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 10Sale65.8410,343680,94231,606Mar 12 06:53 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 06Option Exercise0.001,043059,141Mar 10 04:53 PM
Caldarella Joseph CSVP & ControllerMar 06Option Exercise0.001,931074,668Mar 10 04:53 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 06Option Exercise0.001,043040,624Mar 10 04:51 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 06Option Exercise0.0029,2400374,863Mar 10 04:51 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 06Option Exercise0.002,528030,053Mar 10 04:52 PM
Nielsen AnneChief Compliance & Ethics OffMar 06Option Exercise0.00724048,631Mar 10 04:53 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 06Option Exercise0.002,390054,339Mar 10 04:53 PM
Cuss Francis MEVP & CSOMar 06Option Exercise0.003,0090261,937Mar 10 04:54 PM
Caforio GiovanniChief Operating OfficerMar 06Option Exercise0.002,889061,986Mar 10 04:52 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 06Option Exercise0.007,3230171,251Mar 10 04:52 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 06Option Exercise0.005,5730298,970Mar 10 04:52 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 06Sale66.2410,468693,45249,031Mar 10 04:53 PM
Nielsen AnneChief Compliance & Ethics OffMar 02Option Exercise0.001,033044,363Mar 04 05:14 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 02Option Exercise0.009,7470108,016Mar 04 05:14 PM
Cuss Francis MEVP & CSOMar 02Option Exercise0.003,7030245,358Mar 04 05:14 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 02Option Exercise0.003,182040,705Mar 04 05:14 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 02Option Exercise0.001,360051,827Mar 04 05:12 PM
Caldarella Joseph CSVP & ControllerMar 02Option Exercise0.002,475064,025Mar 04 05:13 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 02Option Exercise0.001,174035,654Mar 04 05:13 PM
Caforio GiovanniChief Operating OfficerMar 02Option Exercise0.001,494046,893Mar 04 05:13 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 02Option Exercise0.0033,5310416,594Mar 04 05:13 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 02Option Exercise0.008,250060,609Mar 04 09:38 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 02Option Exercise0.008,249043,860Mar 04 09:38 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 02Option Exercise0.0019,995034,176Mar 04 09:38 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 02Option Exercise0.0044,0840316,255Mar 04 09:39 PM
Caforio GiovanniChief Operating OfficerMar 02Option Exercise0.0022,851070,125Mar 04 09:37 PM
Cuss Francis MEVP & CSOMar 02Option Exercise0.0023,8030270,105Mar 04 09:37 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 02Option Exercise0.0018,907060,423Mar 04 09:37 PM
Nielsen AnneChief Compliance & Ethics OffMar 02Option Exercise0.005,725050,278Mar 04 09:37 PM
Caldarella Joseph CSVP & ControllerMar 02Option Exercise0.0015,271079,730Mar 04 09:36 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 02Option Exercise0.00231,2800643,964Mar 04 09:36 PM
LEUNG SANDRAGeneral Counsel & SecretaryFeb 17Option Exercise25.4515,000381,750275,656Feb 18 05:32 PM
LEUNG SANDRAGeneral Counsel & SecretaryFeb 17Sale60.3911,746709,282263,910Feb 18 05:32 PM
Moed Samuel JSVP, Strat Plan & AnalysisFeb 12Sale59.263,880229,93334,480Feb 13 04:38 PM
Moed Samuel JSVP, Strat Plan & AnalysisFeb 06Option Exercise22.1427,938618,54759,838Feb 10 06:11 PM
Moed Samuel JSVP, Strat Plan & AnalysisFeb 06Sale60.1521,4781,291,98838,360Feb 10 06:11 PM
CORNELIUS JAMES MDirectorJan 30Sale60.6050,0003,029,975119,464Feb 03 06:18 PM
ANDREOTTI LAMBERTOChief Executive OfficerJan 29Option Exercise25.45112,5002,863,125473,309Feb 02 07:05 PM
CAMPBELL LEWIS BDirectorJan 29Option Exercise26.252,50065,6252,500Feb 02 07:05 PM
CAMPBELL LEWIS BDirectorJan 29Sale60.892,500152,2270Feb 02 07:05 PM
Schmukler Louis SPres., Global Mfg. & SupplyJan 29Sale60.735,250318,85014,182Feb 02 07:05 PM
ANDREOTTI LAMBERTOChief Executive OfficerJan 29Sale61.1490,2465,518,001383,063Feb 02 07:05 PM
Elicker John ESVP Pub Affairs & Inv RelationJan 03Option Exercise0.00952050,808Jan 06 06:56 PM
ANDREOTTI LAMBERTOChief Executive OfficerDec 05Sale60.3175,0004,522,944360,809Dec 05 05:39 PM
ANDREOTTI LAMBERTOChief Executive OfficerNov 05Sale57.7975,0004,334,153435,809Nov 07 05:13 PM
Cuss Francis MEVP & CSONov 02Option Exercise0.006,6660245,112Nov 04 05:42 PM
Bancroft Charles AEVP & Chief Financial OfficerNov 01Option Exercise0.003,102099,666Nov 04 05:43 PM
ANDREOTTI LAMBERTOChief Executive OfficerOct 24Sale53.0050,0002,650,000510,809Oct 28 04:23 PM
CORNELIUS JAMES MDirectorOct 15Sale48.92100,0004,892,000169,041Oct 17 05:16 PM
ANDREOTTI LAMBERTOChief Executive OfficerOct 06Sale50.9950,0002,549,485560,809Oct 08 06:02 PM
Schmukler Louis SPres., Global Mfg. & SupplyOct 03Option Exercise0.0013,934025,565Oct 06 05:52 PM
Cuss Francis MEVP & CSOSep 16Option Exercise25.1763,6671,602,575302,113Sep 16 05:18 PM
Cuss Francis MEVP & CSOSep 16Sale50.7763,6673,232,074238,446Sep 16 05:18 PM
Caforio GiovanniChief Operating OfficerSep 15Sale49.8726,6911,331,15540,755Sep 16 05:18 PM
Caldarella Joseph CSVP & ControllerSep 10Sale51.037,415378,37761,550Sep 10 04:30 PM
ANDREOTTI LAMBERTOChief Executive OfficerSep 08Sale51.0550,0002,552,430610,809Sep 10 04:30 PM
von Autenried PaulSVP, Enterp. Services & CIOAug 19Sale49.8920,000997,85137,523Aug 19 05:08 PM